HK1163119A1 - 抗體及其用於治療癌症的用途 - Google Patents

抗體及其用於治療癌症的用途

Info

Publication number
HK1163119A1
HK1163119A1 HK12103380.8A HK12103380A HK1163119A1 HK 1163119 A1 HK1163119 A1 HK 1163119A1 HK 12103380 A HK12103380 A HK 12103380A HK 1163119 A1 HK1163119 A1 HK 1163119A1
Authority
HK
Hong Kong
Prior art keywords
cxcr4
treatment
cancer
antibodies
cxcr4 antibodies
Prior art date
Application number
HK12103380.8A
Other languages
English (en)
Inventor
.克林格-阿穆
.格勒尼耶-科薩內爾
Original Assignee
皮埃爾法布雷醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司
Publication of HK1163119A1 publication Critical patent/HK1163119A1/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
HK12103380.8A 2008-10-01 2012-04-05 抗體及其用於治療癌症的用途 HK1163119A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1163119A1 true HK1163119A1 (zh) 2012-09-07

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103380.8A HK1163119A1 (zh) 2008-10-01 2012-04-05 抗體及其用於治療癌症的用途

Country Status (29)

Country Link
US (4) US8557964B2 (zh)
EP (2) EP2172485A1 (zh)
JP (1) JP5723279B2 (zh)
KR (1) KR101671039B1 (zh)
CN (1) CN102209730B (zh)
AR (1) AR073748A1 (zh)
AU (1) AU2009299787B2 (zh)
BR (1) BRPI0920531A2 (zh)
CA (1) CA2738782C (zh)
CL (1) CL2011000730A1 (zh)
CY (1) CY1115572T1 (zh)
DK (1) DK2342233T3 (zh)
ES (1) ES2503732T3 (zh)
GE (1) GEP20146084B (zh)
HK (1) HK1163119A1 (zh)
HR (1) HRP20140899T1 (zh)
IL (1) IL212066A (zh)
MA (1) MA32928B1 (zh)
MX (1) MX2011003509A (zh)
NZ (1) NZ592363A (zh)
PL (1) PL2342233T3 (zh)
PT (1) PT2342233E (zh)
RS (1) RS53578B1 (zh)
RU (1) RU2573897C2 (zh)
SI (1) SI2342233T1 (zh)
TW (1) TWI469792B (zh)
UA (1) UA102867C2 (zh)
WO (1) WO2010037831A1 (zh)
ZA (1) ZA201102969B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Hivの治療用抗体
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
KR101809072B1 (ko) * 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
EP3858997A1 (en) 2013-09-23 2021-08-04 Wilson Wolf Manufacturing Corporation Improved methods of genetically modifying animal cells
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途(一)
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10973852B2 (en) 2016-01-25 2021-04-13 Nantcell, Inc. NK cells with altered CXCL12/CXCR4 signaling
WO2017203799A1 (ja) * 2016-05-25 2017-11-30 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3576787A4 (en) * 2017-01-31 2020-09-23 MSM Protein Technologies Inc. ANTI-CXCR4 ANTIBODY
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN117003876A (zh) * 2023-08-31 2023-11-07 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US9029097B2 (en) * 2005-02-16 2015-05-12 Universite De Montreal Biosensors for monitoring receptor-mediated G-protein activation
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗cxcr4抗体

Also Published As

Publication number Publication date
RU2573897C2 (ru) 2016-01-27
RS53578B1 (en) 2015-02-27
US8557964B2 (en) 2013-10-15
CY1115572T1 (el) 2017-01-04
ZA201102969B (en) 2011-12-28
KR20110081229A (ko) 2011-07-13
AU2009299787A2 (en) 2011-06-02
TW201018483A (en) 2010-05-16
AR073748A1 (es) 2010-12-01
AU2009299787B2 (en) 2015-06-18
SI2342233T1 (sl) 2014-10-30
GEP20146084B (en) 2014-05-13
US20140050661A1 (en) 2014-02-20
EP2342233B1 (en) 2014-06-25
CN102209730B (zh) 2014-11-05
CN102209730A (zh) 2011-10-05
US20110294156A1 (en) 2011-12-01
DK2342233T3 (da) 2014-09-29
US20110287451A1 (en) 2011-11-24
US20110020218A1 (en) 2011-01-27
ES2503732T3 (es) 2014-10-07
HRP20140899T1 (hr) 2014-11-07
JP5723279B2 (ja) 2015-05-27
IL212066A0 (en) 2011-06-30
JP2012504401A (ja) 2012-02-23
CA2738782C (en) 2017-11-28
KR101671039B1 (ko) 2016-11-01
US9388248B2 (en) 2016-07-12
WO2010037831A1 (en) 2010-04-08
IL212066A (en) 2015-05-31
MA32928B1 (fr) 2012-01-02
EP2342233A1 (en) 2011-07-13
PT2342233E (pt) 2014-10-03
TWI469792B (zh) 2015-01-21
PL2342233T3 (pl) 2014-11-28
NZ592363A (en) 2012-08-31
RU2011115559A (ru) 2012-11-10
CA2738782A1 (en) 2010-04-08
UA102867C2 (uk) 2013-08-27
BRPI0920531A2 (pt) 2021-02-23
CL2011000730A1 (es) 2012-02-03
AU2009299787A1 (en) 2010-04-08
MX2011003509A (es) 2011-05-02
EP2172485A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
HK1163119A1 (zh) 抗體及其用於治療癌症的用途
IL247183B (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL213070A0 (en) Methods for the treatment of infections and tumors
EP2277049A4 (en) AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER
PL2532364T3 (pl) Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
EP2216344A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
HK1159498A1 (zh) 用於治療癌症的方法和組合物
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
EP2652508A4 (en) USE OF ANTI-CXCL13 ANTI-CXCR5 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1178910A1 (zh) 用於治療癌症的人源化抗 抗體
GB0807018D0 (en) Antibodies and treatment
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2377891A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
EP2420515A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2411031A4 (en) Methods and compositions for the treatment of cancer
EP2123676A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
HK1209754A1 (zh) 用於治療癌症的化合物和方法
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
IL211752A0 (en) Antibody combinations and use of same for treating cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191001